In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Makes its Biggest External Play Yet With Long-Term Regeneron Deal

Executive Summary

The billion-dollar expansion of Sanofi’s R&D relationship with antibody platform firm Regeneron Pharmaceuticals, announced in November, effectively turns Regeneron into Sanofi’s external antibody shop through 2017 and gives Paris-based Sanofi a potential bounty of monoclonal antibodies for its pipeline. just as its old-line small molecule products such as the blockbuster blood-thinner clopidogrel (Plavix) face generic competition for the first time.

You may also be interested in...



Pharma: Serious About Change?

Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.

Pharma: Serious About Change?

Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.

Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron

The Japanese pharma is paying $165 million upfront for continued access to the fully human monoclonal antibody discovery platform through 2018.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV003239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel